Clinical Data, Inc. (NASDAQ:CLDA), a leader in the development of targeted therapeutics and predictive tests from its growing portfolio of proprietary genetic biomarkers, announced that it has initiated the second of its two pivotal trials of Vilazodone, the Company's novel drug candidate for the treatment of depression. This double-blind, placebo-controlled clinical trial is designed to assess the efficacy and safety of Vilazodone.
Researchers have discovered perhaps the strongest evidence yet linking variation in a particular gene with anxiety-related traits.
Mary Agnes Carey, associate editor of CQ HealthBeat, examines a Government Accountability Office report on Medicare Advantage costs, a scheduled House vote on mental health parity legislation, Senate approval of the